Please login to the form below

Not currently logged in
Email:
Password:

China streamlines import of HIV drugs

China's State Food and Drug Administration will streamline approval procedures for importing drugs to treat the estimated 85,000 HIV patients in the country

China's State Food and Drug Administration (SFDA) will streamline approval procedures for importing drugs to treat the estimated 85,000 AIDS patients in the country.

The approval was based on the release of a report into HIV/AIDS prevalence and prevention assessment in the region for 2007 on 29 November, which stated that about 700,000 people in the country are living with AIDS and HIV.

Zhang Wei, director with the SFDA's drug registration department, said that a streamlined approval method had been adopted for imports of drugs which showed significant clinical effects in treating diseases such as AIDS and cancer.

A regulation on drug approval was also amended in July 2007, making procedures more transparent and efficient and could see certain procedures going faster in certain cases.

To date, only seven HIV drugs are prescribed for first-line anti-retroviral treatment in China, with 37,497 AIDS patients receiving free treatment through government aid programmes. About 10 percent of patients on the first-line treatment, however, develop resistance after taking the drugs for one year and have to switch to the second-line drugs to survive, according to the Chinese Health Ministry.

Approval for the import of US-based Gilead Science's TDF, a drug in the second line of triple therapy in HIV, is currently under way and should be completed in time. Gliead filed the required application in August 2007.

Gilead markets TDF in the US under the brand name Viread (tenofovir) and as a part of its Atripla (efavirenz/ tenofovir/ emtricitabine) combination product. The SFDA has also approved the import of lopinavir/ritonavir, manufactured by US-based Abbott.

The Ministry of Health launched a pilot scheme on second-line therapy in Henan, Anhui and Hubei provinces, which will eventually be expanded to the whole country.

Global sales for Bristol-Myers Squibb (BMS) and Gilead's combinations treatments Atripla and Truvada racked up sales of USD 650m and USD 1.1bn respectively during the first nine months of 2007.

3rd December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics